Human parvovirus B19 and blood products

Vox Sanguinis

Volumn 72, Issue 1, 1997, Pages 1-10

  Prowse, C ^a   Ludlam, C A ^b   Yap, P L ^b  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT THERAPY; BLOOD DONOR; ERYTHEMA INFECTIOSUM; ERYTHROCYTE LIFESPAN; FRACTIONATION; HEMOPHILIA; HUMAN; IMMUNE DEFICIENCY; PARVOVIRUS; PATHOPHYSIOLOGY; PLASMA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING; VIREMIA; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

EID: 0031034996     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1997.00001.x     Document Type: Review

References (128)

1. Prowse CV, Follett E, Prince A: Hepatitis A virus transmission by blood products. Vox Sang 1994;67(suppl 1):1-85.
2. Harris JW: Parvovirus B19 for the haematologist. Am J Hematol 1992;39:119-130.
3. Young NS:B19 parvovirus. Baillières Clin Haematol 1995;8:25-56.
4. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DAJ: Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-265.
5. Sato H, Hirata J, Furukawa M, et al: Identification of the region including the epitope for a monoclonal antibody which can neutralise human parvovirus B19. J Virol 1991;65:1667-1672.
6. Sato H, Hirata J, Kuroda N, et al: Identification and mapping of neutralising epitopes of human parvovirus B19 by using human antibodies. J Virol 1991;65:5845-5940.
7. Bansal GP, Hatfield JA, Dunn FE, et al: Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993;167:1034-1044.
8. Spalholz BA, Tattersall P: Interaction of minute virus of mice with differentialed cells: Strain-dependent target cell specificity is mediated by intracellular factors. J Virol 1983;46:937-943.
9. Ozawa K, Ayub J, Kajigaya S, et al: The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. Virol 1988;62:2884-2889.
10. Anderson MJ, Jones SE, Minson AC: Diagnosis of human parvovirus infection by dot-blot hybridisation using cloned viral DNA. J Med Virol 1985;15:163-172.
11. Chorba TL, Coccia P, Holman RC, et al: Role of parvovirus B19 in aplastic crisis and erythemia infectiosum (fifth disease). J Infect Dis 1986; 154:383-393.
12. Koch WC, Adler SP: Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989:8:83-87.
13. Gillespie SM, Cartter ML, Asch S, et al: Occupational risk of human parvovirus B19 infection for school and day care personnel during an outbreak of erythemia infectiosum. J Am Med Assoc 1990;263:2061-2065.
14. Dowell SF, Torok TJ, Thorp JA, Hedrick J, Erdman DD, Zaki SR, Hinkle CJ, Bayer WL, Anderson LJ: Parvovirus B19 infection in hospital workers: Community or hospital acquisition? J Infect Dis 1995;172:1076-1079.
15. Bell LM, Naides SJ, Stoffman P, et al: Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989;322:485 -491.
16. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus like particles in human sera. Lancet 1975;i:72-73.
17. Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CLR, Cohen BJ, Mortimer PP, Pereira MS: Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983;i:1378.
18. Anderson LJ, Torok TJ: Human parvovirus B19. N Engl J Med 1989;321:536-538.
19. Pattison JR: Human parvovirus B19. BMJ 1994; 308:149-150.
20. Brown KE, Anderson SM, Young NS: Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 1993;262:114-117.
21. Brown KE, Hibbs JR, Gallinella G, Anderson SM, Lekman EH, McCarthy P: Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994;330:1192-1196.
22. Brown KE, Young NS: Parvovirus B19 infection and hematopoiesis. Blood Rev 1995;9: 176-182.
23. Young NS, Harrison M, Moore JG, et al: Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 1984;74:2024 2032.
24. Anderson LJ, Tsou C, Parker RA, Chorba TL, Woffe H, Tattersall P, Mortimer PP: Detection of antibodies and antigen of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986;24:522-526.
25. Cohen BJ, Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988;25:151-153.
26. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, D'Oiron R, Tehernia G: Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hématol 1994;36:449-453.
27. Peerlinck K, Goubau P, Reybrouck R, Desmyter J, Vermylen J: Parvovirus B19 antibodies in patients with haemophilia A. Thromb Haemost 1995;73:555-556.
28. Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FGH: Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990;58:177-181.
29. Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glomstein A: Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991;23:675-679.
30. Matsunaga Y, Goh KT, Utagawa E, Moroi N: Low prevalence of antibody of human parvovirus B19 in Singapore. Epidemiol Infect 1994; 113:537-540.
31. Yamashita K, Matsunaga Y, Taylor-Wiederman J, Yamazaki S: A significant age shift of the human parvovirus B19 antibody prevalence in young adults observed in a decade. J Med Sci Biol 1992;45:49-58.
32. Tarar MR, Stevenson J: Measles, rubella and parvovirus B19 in Scotland. SCIEH Weekly Rep 1996;30:72-77.
33. Mortimer PP, Luban NLC, Kelleher JF, Cohen BJ: Transmission of serum parvovirus like virus by clotting factor concentrates. Lancet 1983;ii: 482-484.
34. Grosse-Bley A, Eis-Hubinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE: Serological and virological markers of human parvovirus B19 infection in sera of haemophiliacs. Thromb Haemost 1994; 72:503-507.
35. Araujo FM, Koch MC, Araujo AR: Prevalence of parvovirus B19 infection in Portugal. Blood Coagul Fibrinolysis 1995;6:687.
36. Flores G, Juarez JC, Montoro JB, Tusell JM, Altisent C, Juste C, Jardi R: Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia 1995;1:115-117.
37. Ragni MV, Koch WC, Jordan JA: Parvovirus B19 infection in patients with haemophilia. Transfusion 1996;36:238-241.
38. Mosquet B, Lacotte J, Le Querrec A, Petitjean J, Groller G, Moulin M: Atteinte hématologique sévère lors d'une infection à parvovirus B19. Thérapie 1994;49:459-476.
39. Zanella A, Rossi F, Cesana C, Foresti A, Nador F, Binda AS, Lunghi G, Cappellini MD, Furone M, Sircha G: Transfusion transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 1995;35:769-772.
40. Lefrère JJ, Mariotti M: Use of digoxigenin labelled probes for the detection of B19 parvovirus DNA in batches of blood products. Cell Mol Biol 1995;41:985-988.
41. Saldanha J, Minor P: Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996;93:714-719.
42. Reid DM, Reid TMS, Brown T, Rennie JAN. Eastmond CJ: Human parvovirus-associated arthritis: A clinical and laboratory description. Lancet 1985;i:422-425.
43. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA: Human parvovirus arthropathy. Lancet 1985;i:419-421.
44. Naides SJ, Scharosch LL, Foto F, Howard E: Rheumatologic manifestations of human parvovirus infection in adults. Arthritis Rheum 1990; 33:1297-1307.
45. Leventhal LJ, Naides SJ, Freundlich B: Fibromyalgia and parvovirus infection. Arthritis Rheum 1991;34:1319-1324.
46. Kinkel TH, Torok TJ, Ferguson PJ, Durigon EL, Zaki SR, Leung DYM, Harbeck RJ, Gelfand EW, Saulsbury FT, Hollister JR, Anderson LJ: Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent. Lancet 1994;343:1255-1258.
47. Cope AP, Jones A, Shafi MS, Maini RN: Possible induction of systemic lupus erythematosis by human parvovirus. Ann Rheum Dis 1992;51: 803-804.
48. Nigro G, Zerbini M, Krzysztofiak A, Gentilomi G, Porcaro MA, Mango T, Musiani M: Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet. 1994;343:1260-1261.
49. Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J: Persistence of B19 infection in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992;12:147-151.
50. Nikkari S, Luukkainen R, Motton T, Meurman O, Hannonen P, Skurnik M, Toivanen P: Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994;53:106-111.
51. Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Biaese RM, Young NS: Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989;84: 1114-1123.
52. Kerr JR, Curran MD, Moore IE, Coyle PV, Ferguson WP: Persistent parvovirus B19 infection. Lancet 1995;345:1118.
53. Wierenga KJJ, Pattison JR, Brink N, Griffiths M, Miller M, Shah DJ, Williams W, Serjeant BE, Serjeant GR: Glomerulonephritis after human parvovirus infection in homozygous sickle cell disease. Lancet 1995;346:475-476.
54. Public Health Service Working Party on 'Fifth' Disease: Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990; 300:1166-1170.
55. Heegaard ED, Hornsleth A: Parvovirus: The expanding spectrum of disease. Acta Paediatr 1995;84:109-117.
56. Kerr JR, Boyd N: Autoantibodies following parvovirus B19 infection. J Infect 1996;32:41-47.
57. Garciatapia AM, Delalamo CFG, Giron JA, Mira J, Delarubia F, Martinezrodriguez A, Martinreira MV, Lopezcaparros R, Caliz R, Caballero MS, Bascunana A: Spectrum of parvovirus B19 infection: Analysis of an outbreak of 43 cases in Cadiz, Spain. Clin Infect Dis 1995;21:1424-1430.
58. Futo F, Saag KG, Scharosch LL, et al: Parvovirus B19 specific DNA in bone marrow from B19 arthropathy patients. Evidence for B19 virus persistence. J Infect Dis 1993;167:1255-1258.
59. Sasaki T, Murai C, Muryoi T, Takahashi Y, Munakata Y, Sugamura K, Abe K: Persistent infection of human parvovirus B19 in a normal subject. Lancet 1995;346:851.
60. Karmochkine M, Oksenhendler E, Leruezville M, Jaccard A, Morinet F, Herson S: Persistent parvovirus B19 infection and pure red cell aplasia in Waldenström's macroglobulinemia: Successful treatment with high dose intravenous immunoglobulin. Am J Hematol 1995;50:227-228.
61. Oeda E, Shinohara K, Inque H, Nomiyama J: Parvovirus B19 infection causing severe peripheral blood thrombocytopenia and persistent viremia. Am J Hematol 1994;45:274-275.
62. Cassinotti P, Schultze D, Schlageter P, Chevili S, Siegle G: Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 1993;12:701-704.
63. Kurtzman G, Frickhofen N, Kimball J, et al: Pure red cell aplasia of 19 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-523.
64. Jobanputra P, Davidson F, Graham S, O'Neil H, Simmonds P, Yap PL: High frequency of parvovirus B19 in patients tested for rheumatoid factor. BMJ 1995;311:1542.
65. Jawad ASM: Persistent arthritis after human parvovirus B19 infection. Lancet 1993;341: 494.
66. Naides SJ, Foto F, Scharosch LL: Detection of parvovirus B19 specific DNA sequences in synovial fluid (abstract). Cell Biochem 1995: 45(suppl 15E):157.
67. Nocton JJ, Miller LC, Tucker LB, Schaller JG: Human parvovirus B19 associated arthritis in children. J Pediatr 1993;122:186-190.
68. Cassinotti P, Bas S, Siegl G. Vischer TL: Association between human parvovirus B19 infection and arthritis. Ann Rheum Dis 1995;54: 498-500.
69. Gran JT, Johnsen V, Myklebust G, Nordbo SA: The variable clinical picture of arthritis induced by human parvovirus B19 - Report on seven adult cases and review of the literature. Scand J Rheumatol 1995;24:174-179.
70. Hartman KR, Brown KE, Green SW, Young NS: Lack of evidence for parvovirus B19 viraemia in children with chronic neutropenia. Br J Haematol 1994;84:895-898.
71. Shirono K, Tsuda H: Parvovirus B19 associated haemophagocytic syndrome in healthy adults. Br J Haematol 1995;89:923-926.
72. Muir KW, Fitzsimons E: Human parvovirus infection and transient erythroblastopenia of childhood. Br J Haematol 1992;81:622-632.
73. Nagai K, Morohoshi T, Kudoh T, et al: Transient erythroblastopenia of childhood with megakaryocytopenia associated with human parvovirus B19 infection. Br J Haematol 1992;80:131-132.
74. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S: Human parvovirus B19 infection associated with acute hepatitis. Lancet 1996;347:868-869.
75. Langnas AN: Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 1995;22: 1661-1665.
76. Murray JC, Morad AB: Childhood autoimmune neutropenia and human parvovirus B19. Am J Hematol 1994;47:336.
77. Rodin JF, Quinn DL, Gary GW Jr, et al: Management and outcomes of pregnancies complicated by human B19 parvovirus infection: A prospective study. Am J Obstet Gynecol 1990; 163:1168-1171.
78. Jordan JA: Identification of human parvovirus B19 infection in idiopathic non-immune hydrops fetalis. Am J Obstet Gynecol 1996;174: 37-42.
79. Wright C, Hinchliffe SA, Taylor C: Fetal pathology in intrauterine death due to parvovirus B19 infection. Br J Obstet Gynaecol 1996;103:133-136.
80. Young N: Haematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988;25:159-172.
81. Fairley CK, Smoleniec JS, Caul OE, Miller E: Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995;346: 1335.
82. Mallouh AA, Qudah A: Acute splenic sequestration together with aplastic crisis caused by human parvovirus B19 in patients with sickle cell disease. J Pediatr 1993;122:593-595.
83. Frickhofen N. Abkowitz J, Safford M, et al: Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-I): A treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926-933.
84. Kurtzman G, Cohen B, Myers P, et al: B19 parvovirus infection as a cause of severe anemia in children with acute lymphocytic leukemia in remission. Lancet 1988;ii:1159-1162.
85. Bremner JAG, Beard BJ, Cohen A, Alimenti B, Cantiniaus B, Levy J: Secondary infection with parvovirus B19 in an HIV positive patient. AIDS 1993;7:1131-1132.
86. Nield G, Anderson M, Hawes S, et al: Parvovirus infection after renal transplant. Lancet 1986;ii:1226-1227.
87. Hamon MD, Newland AC, Anderson MJ: Severe aplastic anaemia after parvovirus infection in the absence of underlying haemolytic anaemia. J Clin Pathol 1988;41:1242.
88. Frickhofen N, Reghavachar A, Heit W, et al: Human parvovirus infection. N Engl J Med 1986;314:646.
89. Hanada T, Koike K, Takeya T, et al: Human parvovirus B19 induced transient pancytopenia in a child with hereditary spherocytosis. Br J Haematol 1988;70:113-115.
90. Uike N, Miyamura T, Obama K, Takahira H, Sate H, Kozuru M: Parvovirus B19 associated haemophagocytosis in Evan's syndrome: Aplastic crisis associated by severe thrombocytopenia. Br J Haematol 1993;84:530-532.
91. Pont J, Puchhammer-Stökle E, Chott A, et al: Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 1992;80:160-165.
92. Lefrère JJ: Peripheral thrombocytopenia in human parvovirus infection. J Clin Pathol 1987; 40:469.
93. McClain K, Estrov Z, Chen H, et al: Chronic neutropenia of childhood: Frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol 1993;85:57-62.
94. Cohen BJ, Mortimer PP, Pereira MS: Diagnostic assays with monoclonal antibodies for the human serum parvovirus like virus (SPLV): J Hyg 1983;91:113-130.
95. Cubic HA, Leslie EE, Smith S, O'Neill HJ, Hart H, Cohen BJ, Inglis JM: Use of recombinant human parvovirus B19 antigen in serological assays. J Clin Pathol 1993;46:840-845.
96. Gray JJ, Cohen BJ, Desselberger U: Detection of human parvovirus B19 specific IgM and IgG antibodies using a recombinant viral VP-I antigen expressed in insect cells and estimation of the time of infection by testing for antibody avidity. J Virol Methods 1993;44:11-24.
97. Hilfenhaus S, Cohen BJ, Bates C, Kajigaya S, Young NS, Zambon M, Mortimer PP: Antibody capture haemadherence tests for parvovirus B19 specific IgM and IgG. J Virol Methods 1993;45:27-37.
98. Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JA: Blood donor screening for parvovirus B19. J Virol Methods 1990;30:233-238.
99. Clewley JP: The application of DNA hybridization to the understanding of human parvovirus disease; in Tenover FC (ed): DNA Probes for Infectious Diseases. Boca Raton, CRC Press 1989, pp 211-220.
100. Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR: Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992;81:407-412.
101. Clewley JP: Polymerase chain reaction assay for parvovirus B19 DNA in clinical specimens. J Clin Microbiol 1989;27:2647-2651.
102. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction. J Clin Microbiol 1993;31:323-328.
103. Courouce AM, Beaulieu MJ, Bouchandeau F, Lenel M, Marrec N: Viraemia with human parvovirus. Lancet 1985;i:1218-1219.
104. Silva-Cruz A, Serpa MJA, Barth OM, Nascimento JPD: Detection of the human parvovirus B19 in a blood donor plasma in Rio de Janeiro. Mem Inst Oswaldo Cruz 1989;84:279-280.
105. O'Neill HJ, Coyle PV: Two anti-parvovirus B19 IgM capture assays incorporating a mouse monoclonal antibody specific for B19 viral capsid proteins VPI and VP2. Arch Virol 1992;123:125-134.
106. Hart HF, Graham S, Davidson F, Yap PL, Simmonds P: The distribution of B19 parvovirus and hepatitis A in a large scale coagulation factor VIII concentrate manufacturing process. Submitted.
107. Shiraki H, Tsujimura M, Matsushita K, Sato H, Okochi K, Maeda Y: B19 parvovirus in blood donors. Vox Sang 1994;67(suppl 2):24.
108. Yoto Y, Kudoh T, Haseyama K, et al: Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995;91:1017-1018.
109. Sato H, Takaiwar F, Kojima E, et al: Screening of blood donors for human parvovirus B19. Lancet 1995;346:1237-1238.
110. Morfini M, Azzi A, Zakrewska K, Clappi S, Kolumban P, Longo L, Rossi Ferrini P: Hypoplastic anaemia in a haemophilic first infused with a solvent detergent treated factor VIII concentrate. The role of human parvovirus B19. Am J Hematol 1992;39:149-150.
111. Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJE, Mitchell VE: Symptomatic parvovirus B19 infection and heat treated factor IX concentrates. Lancet 1989;i: 1085.
112. Lefrère JJ, Mariott M, Thauvin M: B19 parvovirus DNA in solvent detergent treated antihaemophilia concentrates. Lancet 1994;343: 211-212.
113. Cohen B, Millar B, Schwind P: Screening blood donations for parvovirus B19. Lancet 1995;346:1631.
114. Bartolomei Corsi O, Azzi A, Morfini A, Fanci R, Rossi Ferrini P: Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25:165-170.
115. Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM: Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally inactivated factor VIII concentrates. Am J Hematol 1992;39: 228-230.
116. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M: Eliminating parvovirus B19 from blood products. Lancet 1994;343: 798.
117. Yee TT, Lee CA, Pasi KJ: Life threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 1995;345:794-795.
118. Morfini M, Azzi A: Draft Protocol for the Assessment of B19 Parvovirus Transmission by Coagulation Factor Concentrates. Factor VIII and Factor IX Subcommittee of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis, Munich, 1992.
119. Prowse CV: Parvovirus B19 and blood products. Lancet 1994;343:1101.
120. Di Napoli G, Bucci E: Human parvovirus B19 after concentrates for haemophilia. Lancet 1994;343:1566.
121. Musian M, Zerbini M, Gentilomi G, Rodorigo G, Derosa V, Gibellini D, Venturoli S, Gallinella G: Persistent B19 parvovirus infections in haemophilia HIV-I infected patients. J Med Virol 1995;46:103-108.
122. Hart HF, Hart WC, Crossley J, Perrie AM, Wood DJ, John A, McOmish F: Effect of terminal dry heat on non-enveloped viruses in coagulation factor concentrates. Vox Sang 1994;67:345-350.
123. Roberts PL: Severe heat treatment of freezedried coagulation factor concentrates: Is hotter necessarily better? Vox Sang 1995;68:61-62.
124. Flores G, Juarez JC, Montoro JB, Tusell JM, Altisent C: Efficacy of high temperature dry heat in inactivating parvovirus. Haemophilia 1996;2:63-64.
125. Hilfenhaus J, Nowak T, Weimer T, Cummins B: Extended investigation of virus inactivation in plasma products by pasteurisation (abstract 0207). Vox Sang 1994;67(suppl 2):40.
126. Horowitz B, Prince AM,Horowitz MS, Watklevicz C: Viral safety of solvent detergent treated blood products; in Brown F (ed): Virological Safety Aspects of Plasma Derivatives. Dev Biol Stand. Basel, Karger, 1993. vol 81, pp 147-161.
127. Schwartz TF, Roggendorf M, Hottentrager B, Stoltz W, Schinn H: Monitoring of experimental parvovirus B19 contamination during factor VIII preparation. J Med Virol 1990;35:28-31.
128. Zaaijer HJ, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN: Reliability of polymerase chain reactions for detection of hepatitis C. Lancet 1993;341:722-724.